Concizumab - CISMeF

Preferred Label : Concizumab;

NCIt definition : A humanized monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI) binding site for factor Xa (FXa), the Kunitz-2 domain, with potential coagulant activity. Upon subcutaneous or intravenous administration, concizumab specifically targets and binds to the Kunitz-2 domain of TFPI, thereby preventing the activity of TFPI. This prevents TFPI from binding to and blocking the active site of FXa. As TFPI reversibly inhibits FXa, concizumab prevents FXa inhibition. This allows for the activation and continuation of the coagulation cascade, which may prevent bleeding in hemophilia and may rebalance hemostasis.;

UNII : 68603V9EAF;

CAS number : 1312299-39-0;

Drug name : Alhemo;

NCI Metathesaurus CUI : CL972162;

Codes from synonyms : 121922;

Details

Origin ID

C166914;

UMLS CUI

C3494079;

Currated CISMeF NLP mapping
- Concizumab [SMS substance]
- concizumab [MeSH Supplementary Concept]
- concizumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- concizumab [MeSH Supplementary Concept]
- concizumab [MeSH concept]
- concizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients